CMS issues regulations implementing the Medicare Improvements to Patients and Providers Act (MIPPA) of 2008
Client Alert | 1 min read | 08.26.11
On August 26, 2011, the Centers for Medicare & Medicaid Services issued regulations implementing MIPPA provisions and finalizing revisions to Medicare Advantage (MA), Medicare Part D, and section 1876 cost plans. The revisions together conform "changes to the MA regulations to implement statutory requirements regarding special needs plans (SNPs), private fee-for-service plans (PFFS), regional preferred provider organizations (RPPO) plans, and Medicare medical savings accounts (MSA) plans, cost-sharing for dual-eligible enrollees in the MA program and prescription drug pricing, coverage, and payment processes in the Part D program, and requirements governing the marketing of Part C and Part D plans." These regulations are set to go into effect 60 days after publication in the Federal Register, which is slated for Sept. 1, 2011.
Since then, the final rule has been issued and is now available on the Public Inspection Desk. The rule finalizes revisions to regulations governing Medicare Advantage (MA), Medicare Part D, including "This final rule will go into effect 60 days after publication in the Federal Register, which is slated for Sept. 1."
Insights
Client Alert | 3 min read | 05.23.25
Executive Order Seeks Most-Favored-Nation Drug Pricing and HHS Announces Price Targets
On May 12, 2025, President Trump issued an Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which aims to reduce the costs of prescription drugs and biologics for American consumers and other payers. This Order revives a plan from President Trump’s first term and follows his April Executive Order, “Lowering Drug Prices by Once Again Putting Americans First,” which also sought to reduce drug prices. With drug prices in the United States nearly three times higher than many other countries, this second Order asks drug manufacturers to adopt Most-Favored-Nation (MFN) pricing for drugs sold in the United States or face potential regulation. MFN pricing would tether drug prices offered in the United States to the lower-cost prices offered in other comparably developed nations, such as Canada, Germany, or the United Kingdom.
Client Alert | 4 min read | 05.22.25
Opportunities for Procurement on the Horizon as UK Concludes Free Trade Agreement With India
Client Alert | 2 min read | 05.22.25
What Trump’s Nominee for IRS Commissioner Could Mean for Employee Retention Tax Credit Enforcement
Client Alert | 3 min read | 05.20.25
